Liraglutide Plus Metformin: A Phase 2 Study for Type 2 Diabetes

Type 2 Diabetes (T2D) is a prevalent metabolic condition characterized by high blood glucose. Standard treatment often begins with metformin, sometimes supplemented by other oral hypoglycaemic agents (OHAs) like sulphonylureas (SUs). Despite these options, there's an ongoing need for more effective combination therapies to achieve optimal glycemic control and mitigate disease progression. This study investigated the efficacy of adding liraglutide to metformin compared to monotherapy or metformin-SU combinations in T2D patients.

While specific quantitative results on HbA1c reduction, fasting plasma glucose, or body weight changes are not detailed in the provided abstract, the study's primary aim was to assess the effect on glycemic control. The combination of liraglutide and metformin was hypothesized to demonstrate superior glycemic control compared to either monotherapy. The trial design suggests that the liraglutide plus metformin arm was expected to show a more pronounced improvement in blood sugar regulation than metformin alone or the metformin-glimepiride combination. The primary objective was to evaluate the impact of liraglutide as an add-on to metformin on glycemic control in Type 2 Diabetes patients. Outcomes would typically include changes in HbA1c levels, fasting plasma glucose, and other glycemic parameters to quantify the treatment effects.